TransMedics' NOP advances organ transplantation with improved outcomes & cost reductions. See why I rate TMDX stock a strong ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

Solid Organ Transplant Segment to Dominate the Organ Transplant Diagnostics Market (by Transplant Type) The solid organ transplant segment is expected to dominate the organ transplant diagnostics ...

“These guidelines are because lung transplant recipients with obesity, defined by BMI of 30 or greater, are more than twice as likely to develop early lung injury — primary graft dysfunction ...

US biotech Equillium reported Thursday that its lead drug candidate itolizumab failed to meet the main objective in a Phase III trial for patients with acute graft-versus-host disease, sending shares ...

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a critical therapeutic strategy for treating conditions such as hematological ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Mesoblast filed a request for a Type B meeting during the last quarter, in line with previous guidance, and expects to have the meeting during this quarter. The meeting will be held under Mesoblast’s ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...